RedHill Biopharma Ltd.

RDHL Nasdaq SEC CIK 1553846
Follow RedHill Biopharma Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2025 USD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50M$100MFY14FY16FY18FY20FY22FY24
Show the numbers
YearRevenueNet income
FY24$8M−$8.3M
FY23$6.5M$23.9M
FY22$61.8M−$71.7M
FY21$85.8M−$97.7M
FY20$64.4M−$76.2M
FY19$6.3M−$42.3M
FY18$8.4M−$38.8M
FY17$4M−$45.5M
FY16$101K−$29.4M
FY15$3K−$21.1M
FY14--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−800000%−600000%−400000%−200000%0%200000%FY14FY16FY18FY20FY22FY24
Show the numbers
YearGross marginOperating marginNet margin
FY2460.3%−181.7%−102.8%
FY2347%193.4%366.2%
FY2246.1%−69.3%−116%
FY2142.4%−94.6%−114%
FY2042.7%−99%−118.4%
FY1964.1%−686.7%−672.5%
FY1866.1%−470.5%−464.4%
FY1746.9%−1297%−1136.6%
FY16100%−30240.6%−29079.2%
FY15100%−733400%−703000%
FY14---
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY14FY16FY18FY20FY22FY24
Show the numbers
YearFree cash flow
FY24−$9.4M
FY23−$35.8M
FY22−$29.4M
FY21−$65.2M
FY20−$49M
FY19−$40.9M
FY18−$34.5M
FY17−$44.9M
FY16−$28.3M
FY15−$17.8M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • RedHill Biopharma Ltd.
  • Healthcare median
−800000%−600000%−400000%−200000%0%200000%FY14FY16FY18FY20FY22FY24
Show the numbers
YearRedHill Biopharma Ltd.Healthcare median
FY24−102.8%−47%
FY23366.2%−58%
FY22−116%−80.4%
FY21−114%−71.9%
FY20−118.4%−62.2%
FY19−672.5%−46.3%
FY18−464.4%−49.6%
FY17−1136.6%−45.9%
FY16−29079.2%−36%
FY15−703000%−38.4%
FY14-−35.5%